Eddie Sulivan, SAB Biotherapeutics president and CEO, joined Innovation to discuss the recent advancements made by his company.
SAB Biotherapeutics announced its anti-Ebola immunotherapy provided 100% protection against a lethal dose of the Ebola virus in a recent animal study published in The Journal of Infectious Diseases.
The Ebola virus disease is a severe, often fatal illness in humans. There is currently no licensed treatment proven to neutralize the virus.